A clinical-stage pharmaceutical firm centered on the discovery.

, a clinical-stage pharmaceutical firm centered on the discovery, commercialization and development of first-in-course glaucoma therapies, today announced dosing of the 1st patients signed up for the Organization's Phase 2b study of PG324, a novel, fixed-mixture of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most prescribed glaucoma medication widely. The 28-day Stage 2b scientific trial is likely to enroll approximately 300 patients with glaucoma or ocular hypertension and will evaluate two concentrations of PG324 to latanoprost and to AR-13324, all dosed once daily.The resting-state study, Changes in Intrinsic Connectivity of the Brain's Reading Network subsequent Intervention in Kids with Autism, is published online before print in the journal MIND Mapping. Co-authors are Murdaugh and Jose Maximo, UAB Division of Psychology.. 2014 Safety & Health Expo to be held on 17-19 June, London The biggest UK national event reports 25 per cent growth in companies taking part in the 2014 exhibition The UK's flagship event for health insurance and protection is on course for a remarkable year as the event is nearing a sell out with an increase of than five months to go.